Nearly a year after Labcorp struck a deal for certain diagnostics assets from BioReference Health, the lab-testing giant is ...

LH inks new agreement to acquire BioReference Health's oncology and related clinical testing services businesses.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Voyager Therapeutics (VYGR – Research Report), ...

The independent laboratory company has entered an agreement to acquire BioReference Health's oncology diagnostic services.

Labcorp has been a great trade, beating the S&P 500 by 6.9%. Its stock price has climbed to $255.01, representing a healthy ...

Labcorp will acquire BioReference Health's oncology diagnostics operations as the lab company works to expand in high-growth ...

This was the stock's sixth consecutive day of losses.

Truist analyst David MacDonald notes Labcorp (LH) announced that the company has reached an agreement to acquire oncology-focused lab testing ...

Labcorp Holdings has signed a deal to buy certain assets of OPKO Health's BioReference Health unit for up to $225 million. Labcorp on Tuesday said it will pay $192.5 million at closing for ...

Labcorp Holdings Inc. LH, or Labcorp, is prioritizing key specialty testing areas, such as oncology, women’s health, autoimmune disease and neurology, aiming to tap into strong growth opportunities.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...